Eli Lilly Stock Surges 17% on Positive Orforglipron Trial Data
Eli Lilly’s stock soared by as much as 17% after positive phase-three trial data was released for orforglipron, a GLP-1 weight-loss pill. The results showed that the once-daily pill reduced patients’ weight by an average of 16 pounds and lowered their A1C levels by an average of 1.3-1.6%. This news gives Eli Lilly the green … Read more